|
CDC25A expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.85029769284029E-11 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.37070355066271E-11 |
| Normal-vs-Stage2 |
1.166640E-01 |
| Normal-vs-Stage3 |
1.22650001266322E-10 |
| Normal-vs-Stage4 |
2.19819717983682E-11 |
| Stage1-vs-Stage2 |
4.281300E-03 |
| Stage1-vs-Stage3 |
3.796000E-01 |
| Stage1-vs-Stage4 |
4.063600E-02 |
| Stage2-vs-Stage3 |
1.758140E-03 |
| Stage2-vs-Stage4 |
1.446980E-04 |
| Stage3-vs-Stage4 |
2.077800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
4.55191440096314E-15 |
| Normal-vs-AfricanAmerican |
1.01210000003071E-06 |
| Normal-vs-Asian |
1.36790001548093E-09 |
| Caucasian-vs-AfricanAmerican |
5.286400E-01 |
| Caucasian-vs-Asian |
4.834600E-01 |
| AfricanAmerican-vs-Asian |
9.229200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
9.17239950659621E-10 |
| Normal-vs-Female |
1.02659991618737E-10 |
| Male-vs-Female |
7.079600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.88624679711802E-12 |
| Normal-vs-Age(41-60Yrs) |
1.59239288421986E-12 |
| Normal-vs-Age(61-80Yrs) |
4.644400E-04 |
| Normal-vs-Age(81-100Yrs) |
7.304700E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
6.780200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.152190E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.055800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
5.420800E-03 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.233400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.859400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.314190E-02 |
| Classical-VS-Follicular |
1.50169987556126E-10 |
| Classical-VS-Other |
5.788400E-01 |
| Classical-VS-Normal |
2.88269408343922E-12 |
| Tall-VS-Follicular |
1.48381307241152E-12 |
| Tall-VS-Other |
6.875200E-01 |
| Tall-VS-Normal |
1.63646873829748E-12 |
| Follicular-VS-Other |
8.442400E-04 |
| Follicular-VS-Normal |
6.250000E-01 |
| Other-VS-Normal |
3.777400E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.58514999999415E-05 |
| Normal-vs-N1 |
1.55431223447522E-15 |
| N0-vs-N1 |
4.50830484055587E-11 |
|
|
